Cardiovascular molecular imaging is a relatively young but rapidly expanding discipline that consists of a biologically-targeted approach to the assessment of physiologic and pathologic processes in vivo. This novel approach to imaging involves the integration of multiple disciplines such as cell and molecular biology, chemistry, and imaging sciences. The ultimate goal is quantitative assessment of cardiovascular processes at the cellular and molecular level, moving beyond traditional diagnostic information, in order to guide individually tailored therapy. In fact, it is likely that specific approaches to molecular imaging will be developed in tandem with the development of novel therapeutic strategies. Recent advances in probe development and imaging systems have contributed to evolution of molecular imaging toward clinical translational. These include technological progress in traditional imaging platforms; along with the emergence of newer imaging modalities such as photoacoustic imaging. In addition, hybrid imaging (e.g. nuclear imaging with CT or MRI) has the potential for improved spatial localization, and more accurate quantification by coupling anatomic and biological information. In addition to potential clinical applications that address existing diagnostic gaps in cardiovascular medicine, molecular imaging allows for unique approaches to studying pathophysiology. This chapter is intended to provide an overview of the state of the art in cardiovascular molecular imaging, highlighting how it may improve the management of major cardiovascular diseases.
Targeted Nanoparticles for Cardiovascular Molecular Imaging
